ReviewHuman vaccines & immunotherapeutics2016
Factors contributing to the immunogenicity of meningococcal conjugate vaccines.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.Human vaccines & immunotherapeutics · 2026Trial
- A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.BMC infectious diseases · 2020Trial
- Glycoconjugate Vaccines Against Nosocomial Klebsiella pneumoniae Infections.Advances in experimental medicine and biology · 2026Article
- Immunogenicity of primary and booster MenACWY-TT vaccination in older adults and the importance of IgM.NPJ vaccines · 2025Article
- Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?Human vaccines & immunotherapeutics · 2024Article
- Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities.Open forum infectious diseases · 2024Review
- Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines.ImmunoHorizons · 2024Article
- Impact of Protein Nanoparticle Shape on the Immunogenicity of Antimicrobial Glycoconjugate Vaccines.International journal of molecular sciences · 2024Article
- Analysis of immunogenicity and purification methods in conjugated polysaccharide vaccines: a new approach in fighting pathogenic bacteria.Frontiers in immunology · 2024Review
- Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines.ACS infectious diseases · 2023Review
- Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models.Current medical science · 2023Article
- A candidate glycoconjugate vaccine induces protective antibodies in the serum and intestinal secretions, antibody recall response and memory T cells and protects against both typhoidal and non-typhoidalFrontiers in immunology · 2023Article
- Vaccination for meningococcal disease.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022Article
- A Mouse Immunogenicity Model for the Evaluation of Meningococcal Conjugate Vaccines.Frontiers in immunology · 2022Article
- Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection.Nano research · 2022Article
- Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.Frontiers in immunology · 2022Article
- Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines.NPJ vaccines · 2021Review
- Carbohydrate based meningococcal vaccines: past and present overview.Glycoconjugate journal · 2021Review
- Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.Frontiers in cellular and infection microbiology · 2021Review
- Different Long-Term Duration of Seroprotection againstVaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various glycoprotein conjugate vaccines have been developed for the prevention of invasive meningococcal disease, having significant advantages over pure polysaccharide vaccines. One of the most important features of the conjugate vaccines is the induction of a T-cell dependent immune response, which enables both the induction of immune memory and a booster response after repeated immunization. The nature of the carrier protein to which the polysaccharides are chemically linked, is often regarded as the main component of the vaccine in determining its immunogenicity. However, other factors can have a significant impact on the vaccine's profile. In this review, we explore the physico-chemical properties of meningococcal conjugate vaccines, which can significantly contribute to the vaccine's immunogenicity. We demonstrate that the carrier is not the sole determining factor of the vaccine's profile, but, moreover, that the conjugate vaccine's immunogenicity is the result of multiple physico-chemical structures and characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.